الفهرس 
Aim of the workOnly 14 pages are availabe for public view
 |  | from | 71 |  |  |
| | | from | 71 | | |
Abstract
Immune thrombocytopenia (ITP) is an autoimmune disease due to both a peripheral destruction of platelets and an inappropriate bone marrow production. (Audia et al., 2021). Patients with primary ITP are at increased risk of venous and arterial thrombosis compared to the general population. Thrombosis in patients with ITP is associated with 1- and 5- year mortality rates similar to those of serious bleeding. (Lafaurie et al., 2021).
The pathophysiology of cardiovascular disease in ITP patients is that the destruction of the platelet lead to release humoral factors and platelet microparticles. These Platelet microparticles induce thrombin and coagulation activations increaseing the risk of thrombotic events. Also ITP patients have elevated proinflammatory cytokines, suggesting an inflammatory etiology. Inflammatory activity may also affect coagulation states, which could put individuals at risk of thrombotic events. (Chandan et al., 2018). The arterial cardiovascular complication and venous thromboembolism in ITP patient due to the presence of large and immature platelets, thrombosis risk factors, and increased levels of antiphospholipid antibodies. (Chandan et al., 2018). The production of young, activated platelets could promote the onset of thrombosis. Increases in the formation of markers of endothelial activation and neutrophil extracellular traps have also been highlighted in patients with ITP. However, some individual or treatment-related risk factors seem to play an important role in the occurrence of VT and AT in patients with primary ITP. (Lafaurie et al., 2021).
The prognosis of ITP patients may worsen if a cardiovascular or bleeding event occurs, not only because of the event itself but also because of the risks associated with administering anticoagulant or antiplatelet therapy in the presence of thrombocytopenia. (Matzdorff and Beer, 2013).
The aim of our study to assess the role of homocysteine , high-sensitive CRP level and CIMT as a nontraditional CVS risk in addition to traditional CVS risk factors in chronic adult primary immune thrombocytopenic (ITP) patients.
To elucidate this aim 84 subjects 42 of them diagnosed as primary immune thrombocytopenia (ITP), selected from the outpatients and inpatients of Hematology department of Menoufia University Hospitals. We compared the selected ITP patients to controls of 42 normal persons matched by age and gender.
Our patients mean age was (37.76±12.08) and this was nonsignificant difference with controls also there was nonsignificant difference between cases and controls regarding sex, presence of hypertension, presence of DM, smoking state and BMI.There was significant difference between cases and controls regarding levels of HDL and nonsignificant difference between cases and controls regarding levels of cholesterol, TG, LDL.